Showing 1 to 15 of 532 entries
BUY
Healthcare is defensive because you have constant demand for these products and services. Investors should have exposure in this uncertain economy. Her pick here is JNJ, given its strong balance sheet. They offer pharmaceuticals, medical devices and consumer products, so are diversified. Aging demographics will fuel demand.
biotechnology / pharmaceutical
BUY
JNJ vs. PFE Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Sep 16/21, Up 3%) A solid return, considering the year we had. 60 years of consecutive dividend increases. Look at the spinout that's coming. Growth should accelerate. Long term story, not a trade story.
biotechnology / pharmaceutical
BUY
Great company with limited downside, but more possible upside because of its pending break-up. JNJ will get into regular generic drugs which offers growth.
biotechnology / pharmaceutical
TOP PICK
She likes healthcare for being a defensive growth sector. JNJ's balance sheet is very strong, so lots of money to buy companies and grow. They spend a lot on R&D. 70% of revenues come from products that rank #1 or 2. 25% of revenues are from products launched within 5 years. Boasts powerful brands across all segments. Their pharma division is doing well, comprising 55% of company revenues. Drugs coming off-patent can be replaced by 14 drugs totaling a potential $5 billion in sales. They pay a 2.7% dividend they has been increasing for 60 straight years. (Analysts’ price target is $186.88)
biotechnology / pharmaceutical
BUY
Has a great balance sheet and is smart by breaking itself up.
biotechnology / pharmaceutical
TOP PICK
Giant in pharma. Also medical and consumer. Likes pharma, as it's large and has scale. Patents are more insulated from cliffs than its peers. Well staggered expiry dates, diversified components. Spinoff of consumer division should unlock value. Outperformed S&P 500 in 5/6 of the last bear markets. Undemanding 17x earnings. Yield is 2.66%. (Analysts’ price target is $188.56)
biotechnology / pharmaceutical
BUY
It reports Tuesday a transitional quarter. JNJ is breaking into a slower-growth consumer products business, and a higher-growth pharma and medical device division. He expects good numbers even in the interim now.
biotechnology / pharmaceutical
BUY
Healthcare is defensive name in current market. Upcoming spinoffs planned of business units will change profile of company. Long history of rising dividends and solid financial metrics. Is a good company to hold for the long term. Current share price is attractive.
biotechnology / pharmaceutical
HOLD
Hold for long-term? Defensive, low valuation at 16x earnings. Planned consumer spinoff will create value for remaining pharma and medical devices divisions. Hold for the short- and medium-term, then decided which company you want to own after the spinoff.
biotechnology / pharmaceutical
TOP PICK
A traditional recession-proof company. Model price of $171 or so, a 4% overvaluation. Going to split off vaccine division, which is bullish for the stock. Not much upside, but you're looking for companies to get you through a recession deeper than a lot of people realize. Yield is 2.51%. (Analysts’ price target is $190.39)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Mar 03/21, Up 14%) Pharmaceutical sector has remained strong even with tech selloff. Spinning out consumer side of the business which has provided catalyst for return on stock. Current stock price presenting good buying opportunity. Will continue to buy and hold shares in company.
biotechnology / pharmaceutical
COMMENT
Reported a strong last quarter. He was furious when shares fell down. This comes down to market fears, not JNJ itself.
biotechnology / pharmaceutical
BUY
Tuesday morning they reported an inline quarter, except the previously struggling medtech division which is now soaring. JNJ said that after Covid that surgeries would return, so medical device sales would bounce back--and they did. Has a fine balance sheet and does share buybacks. JNJ returns wealth to shareholders.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Mar 30/20, Up 39.2%) Still likes it. Model price of $191.71, still upside of about 10%. Would have been a Top Pick today, but chose a fresh idea instead. In the process of splitting between vaccines and consumer so keep an eye on it, as you might make some money on the transaction.
biotechnology / pharmaceutical
Showing 1 to 15 of 532 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 23

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 24

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 24 stock analysts published opinions about JNJ-N. 23 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

24 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2022-10-04, Johnson & Johnson (JNJ-N) stock closed at a price of $165.62.